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Abstract
Biliary tract cancer (BTC) is often difficult to diagnose definitively, even through histological examination. MicroRNAs
(miRNAs) regulate a variety of physiological processes. In recent years, it has been suggested that profiles for circulating
miRNAs, as well as those for tissue miRNAs, have the potential to be used as diagnostic biomarkers for cancer. The aim of
this study was to confirm the existence of miRNAs in human bile and to assess their potential as clinical biomarkers for BTC.
We sampled bile from patients who underwent biliary drainage for biliary diseases such as BTC and choledocholithiasis.
PCR-based miRNA detection and miRNA cloning were performed to identify bile miRNAs. Using high-throughput real-time
PCR-based miRNA microarrays, the expression profiles of 667 miRNAs were compared in patients with malignant disease
(n=9) and age-matched patients with the benign disease choledocholithiasis (n=9). We subsequently characterized bile
miRNAs in terms of stability and localization. Through cloning and using PCR methods, we confirmed that miRNAs exist in
bile. Differential analysis of bile miRNAs demonstrated that 10 of the 667 miRNAs were significantly more highly expressed
in the malignant group than in the benign group at P,0.0005. Setting the specificity threshold to 100% showed that some
miRNAs (miR-9, miR-302c*, miR-199a-3p and miR-222*) had a sensitivity level of 88.9%, and receiver-operating characteristic
analysis demonstrated that miR-9 and miR-145* could be useful diagnostic markers for BTC. Moreover, we verified the long-
term stability of miRNAs in bile, a characteristic that makes them suitable for diagnostic use in clinical settings. We also
confirmed that bile miRNAs are localized to the malignant/benign biliary epithelia. These findings suggest that bile miRNAs
could be informative biomarkers for hepatobiliary disease and that some miRNAs, particularly miR-9, may be helpful in the
diagnosis and clinical management of BTC.
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Introduction
Among the hepatobiliary malignant neoplasms, biliary tract
cancer (BTC), which includes intra- and extrahepatic cholangio-
carcinoma and gall bladder cancer [1], is increasing in incidence.
BTC arises from the biliary tract epithelia and frequently causes
stricture or obstruction of the bile duct [2]. A consequence of this
obstruction is the retention of bile, which leads to jaundice.
Patients suspected of suffering from BTC and presenting with
clinical symptoms such as jaundice are usually examined using
diagnostic imaging techniques including ultrasonography, com-
puted tomography (CT), and magnetic resonance cholangiopan-
creatography (MRCP). However, these techniques have limited
sensitivity for the detection of BTC [3], and establishing an
accurate diagnosis of cancer in the clinical setting is often difficult
because many benign disorders display similar symptoms. The
result is often a delayed diagnosis of BTC [4]. Early detection of
BTC is critical to patient outcome because a) BTC is associated
with poor prognosis [4]; b) it is characterized by non-responsive-
ness/weaker response to chemotherapy and radiotherapy; and c)
the only curative treatment is surgical resection [5,6]. BTC
patients often undergo surgery before their condition has been
definitively determined to be malignant [7]. Thus, improvement in
diagnostic accuracy for BTC is needed, particularly in light of the
increasing global incidence of the disease. During the last 10 years,
considerable progress has been made in understanding the
pathogenesis of BTC, and several genes and proteins that
contribute to the molecular mechanisms of biliary tract carcino-
genesis have been identified [8,9,10,11,12].
MicroRNAs (miRNAs) are endogenously expressed, short,
noncoding RNAs 18–25 nucleotides in length that repress protein
translation by binding to target mRNAs. In the field of cancer, a
number of studies have been conducted on tissue miRNAs in an
effort to elucidate disease mechanisms and improve upon current
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on the utility of miRNAs from extracellular components, notably
serum and plasma, have been reported [16,17,18]. For example, it
has been shown that placenta-associated circulating miRNAs
correlate with pregnancy progression [16]. Cogswell et al.
recovered miRNAs from cerebrospinal fluid and discovered
Alzheimer’s disease-specific miRNA changes consistent with their
role as potential biomarkers for the disease [19]. Melkonyan et al.
detected a variety of miRNAs in urine, including some excreted
transrenally, and proposed new diagnostic possibilities for
transrenal nucleic acid analysis [20]. Elsewhere, Michael et al.
extracted miRNAs from exosomes obtained from the saliva of
healthy controls and a patient with Sjo ¨gren’s syndrome [21]. In
the context of cancer, miRNAs in serum from patients with breast
cancer and diffuse large-B-cell lymphoma have been shown to be
stable and highly predictive of malignancy and survival [17,18].
These reports suggest significant roles for extracellular miRNAs, in
addition to those of tissue miRNAs, in regulating many
physiological processes. As this field develops, these miRNAs
may become diagnostic and therapeutic targets in clinically
relevant situations. These reports promoted us to speculate that
miRNAs may be present and stable in human bile, just as they are
in other bodily fluids, and that bile-borne miRNAs could be used
as novel biomarkers for BTC.
The major components of human bile are bile acid, cholesterol,
bilirubin, bicarbonates, electrolytes, and water. Bile is produced by
hepatocytes in the liver and flows via the bile duct into the
duodenum, where it assists in lipid digestion and absorption [22].
Like blood, bile can be collected from patients who undergo
diagnostic and/or therapeutic bile drainage. One can therefore
understand the utility of a BTC biomarker in bile and/or serum. A
bile biomarker could expedite the diagnosis of BTC by prompting
further histological examinations such as bile cytology, brush
cytology, and forceps biopsy of the bile duct.
In this study, we first examined whether miRNAs exist and can
be detected in human bile by small RNA library sequencing. Next,
we determined whether the expression of specific miRNAs in bile
differs between patients with cancer and those without cancer
using high-throughput real-time PCR-based miRNA expression
microarrays. Finally, we assessed the potential of bile miRNAs as
novel biomarkers for BTC.
Materials and Methods
Bile collection
The study protocol was approved by the Human Ethics
Committee of Nippon Medical School and the Research Ethics
Committee of Nippon Medical School. Patients who signed a
written informed consent form were enrolled in this study. Bile
samples were collected from 18 patients suffering from biliary
disease (including BTC and choledocholithiasis) who underwent
diagnostic and/or therapeutic bile drainage via percutaneous
transhepatic cholangiodrainage, percutaneous transhepatic gall
bladder drainage, or endoscopic nasobiliary drainage. Nine
patients were diagnosed histologically with adenocarcinoma (seven
with cholangiocarcinoma and two with gall bladder cancer). We
included nine age-matched control patients diagnosed with
choledocholithiasis without current or previous malignancy or an
inflammatory condition (Table 1).
Sample processing and RNA extraction
RNA was extracted from 5 ml of bile from each individual on
the same day as collection. The nucleic acid fraction was obtained
by extraction in phenol–chloroform–isoamyl alcohol (25:24:1)
followed by ethanol precipitation (280uC for 30 min). Total RNA
was obtained using RNAiso Plus (TaKaRa Bio, Tokyo, Japan)
according to the manufacture’s protocol. Extracted RNA samples
were stored at 280uC until use.
Real-time PCR
Total RNA was reverse-transcribed using non-specific primers/
primers specific for each mRNA/miRNA, respectively. Triplicate
samples of the resultant cDNA were subjected to real-time PCR
using TaqMan miRNA primers/probes (Applied Biosystems,
Tokyo, Japan) with a 7300 Real-Time PCR System (Applied
Biosystems).
Small RNA library sequencing of bile miRNAs
miRNA cloning methods are described in our previous report
[23]. Briefly, total RNA samples were extracted from bile using
RNAiso Plus (TaKaRa Bio) (see above) and separated in a
denaturing polyacrylamide gel. The 18–24-nt fraction was then
recovered. Next, 59- and 39-adapters were ligated to the RNAs,
and real-time PCR was carried out. Amplification of the cDNA
fragments was achieved through two consecutive rounds of PCR.
Specific restriction enzyme digestion of the adaptors allowed for
concatemerization of the cDNA into larger fragments. These
fragments were then cloned into a vector to create a cDNA library.
Concatemerization increases the lengths of the informative
sequences that may be obtained from each clone. The small
RNA sequences were analyzed for homology with known
miRNAs. Annotation of the miRNAs was performed using the
miRBase (latest version) homology analysis function.
Real-time PCR-based miRNA expression profiling
Total miRNA (350 ng) was reverse-transcribed using Megaplex
RT Primers (Applied Biosystems). The resulting cDNAs were pre-
amplified using Megaplex PreAmp Primers (Applied Biosystems)
and the pre-amplified products applied to a TaqMan Human
MicroRNA Array Panel (A and B, v2.0). Real-time PCR was
performed using a 7900HT Fast Real-Time System (Applied
Biosystems). The real-time PCR data obtained using the TaqMan
MicroRNA Panel were analyzed with Applied Biosystems software
(SDS ver. 2.3 and RQ manager ver. 1.2). miRNAs expression
levels for patient M9 (see Table 1) were set to 1.0. miRNAs whose
expression was not detectable in patient M9 (see Table 1) were
excluded from further analysis. For quantification, the relative CT
method (DDCT method) was applied. U6 was used as an internal
control. For all 18 patients, this assay was performed using Panels
A and B. We determined the cut-off for significance using a tuning
parameter delta, chosen on the basis of a false-positive rate of zero.
The array data were used to construct receiver-operating
characteristic (ROC) curves by plotting the relationships between
true positives (sensitivity) and false positives (1 – specificity). The
area under the curve (AUC), a measure of discrimination
accuracy, was also calculated.
miRNA stability assay
To evaluate the stability of endogenous miRNAs in bile, we
measured miRNA levels in bile from three individuals that had
been incubated at room temperature for 0 to 24 h. Briefly, 5 ml of
each bile sample was incubated, and miRNAs were extracted and
purified at the scheduled time points using the method described
above. RNA samples were then reverse-transcribed and subjected
to real-time PCR. To measure the stability of exogenous miRNA,
a synthetic Caenorhabditis elegans miRNA (cel-miR-39) was added
to each bile sample at the start of the incubation period (0 h)
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dures. To normalize the data, the synthetic C. elegans miRNA cel-
miR-238 was added to the nucleic acid fraction immediately prior
to reverse transcription to serve as an internal control in the real-
time PCR.
Bile fractionation
Bile is reported to be fractionated into four components by
increasing both the centrifugal force and the duration of
centrifugation [24]. To assess bile miRNA localization, we
fractionated 12-ml samples of bile from three individuals by
differential centrifugation [25] and compared the expression level
of the miRNAs in each fraction (Fig. 1). Relatively large
components such as whole cells, nuclei, and cellular cytoskeletons
sediment at a low speed (1,0006 g for 10 min). Pellets containing
mitochondria, lysosomes, and peroxisomes were obtained at a
medium speed (20,0006 g for 20 min), and microsomes and small
vesicles at high speed (80,0006 g for 1 h). Finally, the smallest
components (e.g., ribosomes, viruses, and large macromolecules)
were collected at a very high speed with a long period of
centrifugation (150,0006 g for 3 h) (Fig. 1). RNA was extracted
from each pellet using RNAiso Plus (TaKaRa Bio) according
to the manufacturer’s protocol, and the expression of some
arbitrarily selected miRNAs was measured by real-time PCR as
described above. The expression level of the mRNA encoding the
biliary epithelial marker cytokeratin 7 (CK-7) was also measured
to verify that the fractionation had been conducted properly
[26,27,28,29].
Results
Confirmation of the existence of miRNAs in human bile
To date, there has been no report on the presence of miRNAs
in bile. Our first priority was to determine whether miRNAs exist
in bile and, if so, to identify them. Real-time PCR with specific
primers/probes demonstrated that miR-21 was present in bile
(Fig. 2A). Using bile as the source material, small RNA library
sequencing verified the presence of several miRNAs, with let-7b
being the most frequently cloned (Fig. 2B and 2C). These
findings showed that miRNAs are present in bile and that bile is an
attractive biological material for miRNA analysis.
High-throughput and quantitative microRNA expression
profiling of bile from patients with biliary tract cancer
To identify bile miRNAs that are aberrantly expressed in biliary
tract diseases, especially biliary tract cancers, we analyzed bile
samples from all 18 patients by real-time PCR-based miRNA
expression profiling (Fig. 3A and Table S1). Relative quantifi-
cation of the data showed that 335 of the 667 miRNAs were
significantly more highly expressed in the malignant group than in
the benign group (P,0.05) (Fig. 3A and Table S1). Of these, we
highlighted 10 miRNAs (miR-9, miR-145*, miR-105, miR-147b, let-
7f-2*, let-7i*, miR-302c*, miR-199a-3p, miR-222* and miR-942)
whose expression was significantly higher at P,0.0005 (Fig. 3A).
Setting the specificity threshold to 100% [17,30] showed that miR-
9, miR-302c*, miR-199a-3p, and miR-222* had a sensitivity level
of 88.9%, indicating that these miRNAs can serve as biological
Table 1. Patient characteristics.
Malignant (n=9)
No. Diagnosis Pathology Sex Age
CEA
(ng/ml)
CA19-9
(U/ml)
M1 Cholangiocarcinoma Adenocarcinoma M 49 1.5 70.8
M2 Cholangiocarcinoma Adenocarcinoma F 78 1.6 35.8
M3 Cholangiocarcinoma Adenocarcinoma M 68 2.9 485.5
M4 Cholangiocarcinoma Adenocarcinoma F 74 1.4 33.1
M5 Gallbladder cancer Adenocarcinoma F 82 7.5 105.7
M6 Gallbladder cancer Adenocarcinoma F 55 0.5 6.1
M7 Cholangiocarcinoma Adenocarcinoma F 71 0.8 51.2
M8 Cholangiocarcinoma Adenocarcinoma F 78 1.5 0.8
M9 Cholangiocarcinoma Adenocarcinoma M 59 2.3 65
Benign (n=9)
No. Diagnosis Pathology Sex Age
CEA
(ng/ml)
CA19-9
(U/ml)
B1 Choledocholithiasis N.A. F 62 W.N.L.
B2 Choledocholithiasis N.A. M 70 W.N.L.
B3 Choledocholithiasis N.A. M 91 W.N.L.
B4 Choledocholithiasis N.A. F 54 W.N.L.
B5 Choledocholithiasis N.A. M 64 W.N.L.
B6 Choledocholithiasis N.A. M 50 W.N.L.
B7 Choledocholithiasis N.A. M 45 W.N.L.
B8 Choledocholithiasis N.A. M 80 W.N.L.
B9 Choledocholithiasis N.A. M 64 W.N.L.
CEA, carcinoembryonic antigen (normal range ,2.5 ng/ml); CA 19-9, carbohydrate 19-9 (normal range ,37 U/ml); N.A., not applicable; W.N.L., within normal limits.
doi:10.1371/journal.pone.0023584.t001
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miR-145*, miR-105, and miR-942 was 77.8%, and that for miR-
147b, let-7f-2*, and let-7i* was 66.7% (Fig. 3B). Additionally, the
area under the ROC-curve analysis showed that miR-9 and miR-
145* could be excellent diagnostic markers for BTC (Fig. 3C).
Taken together, our data show that bile miRNAs, notably miR-9,
have the potential to be used as diagnostic indicators for biliary
tract cancers.
Characterization of bile miRNAs
For bile miRNAs to be used diagnostically in a clinical setting,
they need to be stable. Considering its degradative nature, it was
important to determine how long miRNA integrity could be
maintained in bile. As shown in Fig. 4, we confirmed that the
endogenous bile miRNAs miR-21, let-7c,a n dmiR-9 were stable
in bile and that their expression levels remained high, especially
within 4 hours of 24 hours incubation. However, the exogenous
miRNA cel-miR-238 was immediately degraded when added to
the three individual bile samples (see Materials and Methods).
These observations suggest that endogenous bile miRNAs are
in a stable form that can withstand unfavorable conditions, such
as potent RNase activity and strong acidity, that cause
exogenous miRNAs to be degraded. Furthermore, the fraction-
ation analyses showed that, for all three samples tested, all
miRNAs, including miR-9, were detected in the component
containing biliary epithelial cells, nuclei, and cytoskeletons,
indicating that bile miRNAs reside primarily inside cells and
nuclei. (Fig. 5).
Discussion
Here, we report on the presence and stability of bile miRNAs,
their relative expression levels, as measured by high-throughput
real-time PCR, and differences in the miRNA profiles between
bile samples from patients with benign and malignant biliary tract
disease. After confirming the existence of miRNAs in bile using
specific miRNA primers, we performed a more comprehensive
analysis using miRNA microarrays, which allowed us to test for
the presence of 667 miRNA species. Although this is a small study,
we have confidence that our concept of using miRNAs to
distinguish benign/malignant biliary tract diseases will be
validated as more large-scale studies are conducted in the future.
In addition to proposing the diagnostic use of bile miRNAs, we
have developed reliable methods for extracting and evaluating
miRNAs that are compatible with clinical testing. Comparative
analysis of expression levels identified 10 miRNAs whose levels
differ between malignant and benign conditions (P,0.0005)
(Fig. 3B). ROC analysis identified two of these miRNAs as being
suitable for use as BTC biomarkers (Fig. 3C). Notably, miR-9
showed reliable diagnostic specificity and sensitivity.
In the context of cancer biology, aberrant expression of miR-9
has been associated with metastasis [31,32,33,34]. The miR-9
family is upregulated [32,33] or downregulated [31,35] in various
human cancers. The difference in miR-9 expression seen here may
be similar to the stage-specific regulation that was demonstrated
for miR-200 in liver cancer [36]. Early, when cancer cells become
invasive and undergo epithelial–mesenchymal transition, miR-200
is downregulated, but it is later upregulated during the reepithe-
lialization of distal metastases when cells undergo mesenchymal–
epithelial transition [36]. The mechanism of miR-9 dysregulation
in our study remains unknown but may involve aberrant
methylation of is promoter region [31,34,37] or f activation of
the transcription factor MYC/MYCN [32]. Further functional
studies of miR-9 in BTC are needed.
We subsequently investigated the biochemical characteristics of
miRNAs in the bile. Plasma has been reported to show strong
RNase activity [38]. Mitchell et al. confirmed this RNase activity
and demonstrated that naked miRNAs were subject to degrada-
tion, whereas endogenous miRNAs remained stable in plasma,
even in the presence of potent RNase activity [39]. Interestingly,
we observed similar differences in stability between endogenous
and exogenous miRNAs in bile (Fig. 4). The stability of endo-
genous bile miRNAs makes them suitable as reliable biomarkers in
clinical situations.
How endogenous miRNAs withstand the denaturing conditions
of bile has yet to be explained. Recent studies demonstrated that
most of the circulating miRNAs are found in exosomes, which
protect them from degradation and are responsible for their
excellent stability [40,41,42]. Exosomes are 40–100-nm mem-
brane vesicles of endocytic origin that contain both mRNA and
miRNA. Exosomes can be transferred from one cell to another,
and their components can function in the new environment.
Several miRNA profiling studies have been conducted on
exosomes circulating in the blood [40,41,42]. We initially
presumed that the stability of endogenous bile miRNAs resulted
from their presence in exosomes. However, contrary to our
expectations, cell fractionation experiments revealed that most of
the bile miRNAs were not found in small vesicles but in whole cells
and nuclei (Fig. 5). Although there is no evidence that bile
miRNAs have the same functions as those in serum or plasma, our
findings from the fractionation studies and the PCR analysis of
CK-7 suggest that miRNAs extracted from bile are mainly derived
from intact epithelial cells or malignant cells that have been
Figure 1. Differential centrifugation scheme for bile. Human bile
was subjected to repeated centrifugation at progressively higher
speeds to separate cells and organelles. The centrifugation conditions
(gravity and time) were as follows: low speed, 1,0006 g for 10 min;
medium speed, 20,0006g for 20 min; high speed, 80,0006g for 1 h;
very high speed, 150,0006g for 3 h.
doi:10.1371/journal.pone.0023584.g001
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remain stable in the bile until degradation of the desquamated cells
in which they are contained. Once miRNAs are released from
these structures into the bile, they are likely rapidly degraded.
There is a real need for innovative tools to accurately diagnose
BTC. Currently, the presence of carcinoembryonic antigen (CEA)
and carbohydrate 19-9 (CA 19-9) in serum serve as a standard for
the clinical diagnosis of BTC. As shown in Table 1, however, the
sensitivity of this test is not as high as that achieved by our miRNA
analysis. In eight of nine BTC cases, serum CEA levels did not
increase, even though cancer was present. Additionally, serum
CA-19-9 levels were only increased in certain patients, probably
because of cholestasis. Diagnostic imagining techniques such as
endoscopic ultrasonography (EUS) and intraductal ultrasonogra-
phy are used when BTC is suspected. EUS allows for a good view
of the distal extrahepatic biliary tree, gall bladder, regional lymph
nodes and vasculature [5]. Ro ¨sch et al. compared the diagnostic
accuracy of endoscopic retrograde cholangiopancreatography
Figure 2. Confirmation of the existence of miRNAs in human bile. (A) Real-time PCR-based miRNA detection of miR-21. TaqMan miRNA real-
time PCR using a probe/primers specific for miR-21 was performed on three bile samples and a no-template control sample (NC). Note the lack of a
PCR product in the negative control (NC). (B) Representative chromatogram of the sequencing results after cloning the bile miRNA. Horizontal bars
above the chromatogram indicate each miRNA and linker (see Materials and Methods). (C) Table showing the miRNAs identified from cloning, their
relative frequency, and whether they were cloned from BTC or benign cases.
doi:10.1371/journal.pone.0023584.g002
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strictures. The sensitivity/specificity of diagnosis of malignancy
was 85%/75% for ERCP, 85%/71% for MRCP, 77%/63% for
CT, and 79%/62% for EUS [43]. In a prospective study of
patients with suspected cholangiocarcinoma, EUS had a diagnos-
tic sensitivity of 79% and a specificity of 62% [44]. Moreover, in a
recent meta-analysis, EUS had a sensitivity of 78% and a
specificity of 84% [45]. Intraductal ultrasonography with wire-
guided, thin-caliber, high-frequency probes is performed during
ERCP, and in previous studies showed accuracy rates for
distinguishing benign and malignant strictures of 76–90%
[46,47,48]. In addition to imaging techniques, histological
methods such as bile cytology, brush cytology, and forceps biopsy
are mandatory for definitive diagnosis. Bile cytology and brush
cytology have only modest accuracy rates for determining
malignancy, ranging from 30 to 70% in most published studies
[5,49,50,51,52,53]. Forceps biopsy, which has a higher accuracy
rate than the other histological tests (43 to 81%), is not widely used
because it requires a specialized device and technique [54,55,56].
Similarly, the more specialized EUS-guided fine-needle aspiration
biopsy, with a diagnostic sensitivity of 43 to 86% for biliary
strictures [7,57,58,59,60,61], is currently only used for pancreatic
tumors and inferior bile duct strictures and has not been approved
for use in other conditions. The low diagnostic accuracy of some of
the currently used tests confirms that BTC can be difficult to
diagnose. In view of the poor prognosis for BTC [4], it is desirable
to improve the ease and accuracy of testing. The results of our
investigation indicate that measuring bile miRNAs can improve
the speed and accuracy of diagnosing BTC. Furthermore, bile
analysis is feasible because bile miRNAs are stable and can be
easily extracted and analyzed in clinical settings.
Further investigations with larger numbers of patients and
different study populations as well as studies of differential display
between BTC and pre-malignant diseases such as primary
sclerosing cholangitis are needed to achieve clinical acceptance.
Nevertheless, our results demonstrate that measurement of bile
Figure 4. Time-dependent changes in endogenous and exogenous miRNAs in human bile. The endogenous human bile miRNAs hsa-miR-
21, hsa-let-7c, and hsa-miR-9 are relatively stable. In contrast, the synthetic exogenous miRNA cel-miR-39 was rapidly degraded when added to bile.
doi:10.1371/journal.pone.0023584.g004
Figure 3. Comparison of malignant and benign samples using high-throughput real-time PCR-based miRNA microarrays. (A) miRNA
expression heat map, with miRNAs sorted according to their P-values. Samples are shown in rows, and miRNAs in columns. miRNA expression in
patient M9 (see Table 1) was set to 1.0. Complete microarray results can be found in the Supplementary Information. (B) Dot plot showing the
expression levels of the 10 miRNAs that were significantly more highly expressed in the malignant group than in the benign group (P,0.0005). The
vertical logarithmic axis shows relative quantification values obtained in a TaqMan array assay. Setting the specificity threshold to 100% showed the
sensitivity level to be 88.9% for miR-9, miR-302c*, miR-199a-3p, and miR-222*; 77.8% in miR-145*, miR-105, and miR-942; and 66.7% in miR-147b, let-7f-
2*, and let-7i*. #, median value. (C) ROC curve analysis. The expression profile for each miRNA was used as the input for receiver operating
characteristic (ROC) analysis. The ROC curve shows sensitivity versus 1 – specificity. The area under the curve (AUC), a measure of discrimination
accuracy, was also calculated.
doi:10.1371/journal.pone.0023584.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23584miRNA levels is a practical approach for aiding the assessment of
BTC and is comparable to many current diagnostic methods,
including cytology. We therefore conclude that measurement of
miRNA expression in bile would be helpful in distinguishing
between benign and malignant conditions, especially in cases that
remain undiagnosed. Notably, bile miR-9 has strong potential for
use as a clinical marker of biliary tract cancers.
Supporting Information
Table S1 Expression levels of the miRNAs in bile. A heat
map was constructed using data from the miRNA microarrays
used to analyze bile samples from patients with malignant and
benign disease. miRNA expression in patient M9 (see Table 1)
was set to 1.0. B, analysis of bile from a patient with benign
disease; M, analysis of bile from a patient with malignant disease.
(XLSX)
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